Literature DB >> 18848789

Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.

Hideaki Miyake1, Mototsugu Muramaki, Toshifumi Kurahashi, Atsushi Takenaka, Masato Fujisawa.   

Abstract

The objective of this study was to evaluate the expression levels of multiple potential molecular markers in prostate cancer to clarify the significance of these markers as prognostic indicators in patients undergoing radical prostatectomy (RP). This study included a total of 193 patients with clinically organ-confined prostate cancer who underwent RP without any neoadjuvant therapies. Expression levels of 12 proteins, including Ki-67, p53, androgen receptor (AR), matrix metalloproteinase (MMP)-2, MMP-9, vascular endothelial growth factor, Aurora-A, Bcl-2, clusterin, heat shock protein 27 (HSP27), HSP70, and HSP90, in RP specimens obtained from these 193 patients were measured by immunohistochemical staining. Of the 12 molecules, Ki-67, p53, AR, MMP-2, MMP-9, and HSP27 expression were significantly associated with several conventional prognostic factors. Univariate analysis identified these 6 markers as significant predictors for biochemical recurrence as well, while prostate-specific antigen, Gleason score, seminal vesicle invasion (SVI), surgical margin status (SMS), lymph node metastasis, and tumor volume were also significant. Of these significant factors, Ki-67 expression, SVI, and SMS appeared to be independently related to biochemical recurrence by multivariate analysis. Furthermore, there were significant differences in biochemical recurrence-free survival according to positive numbers of these three independent risk factors. These findings suggest that consideration of expression levels of potential molecular markers in RP specimens, in addition to conventional prognostic parameters, would contribute to accurate prediction of biochemical recurrence following RP in patients with clinically localized prostate cancer, and that combined evaluation of Ki-67 expression, SVI, and SMS would be particularly useful for further refinement of the system in predicting biochemical outcome. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18848789     DOI: 10.1016/j.urolonc.2008.08.001

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  27 in total

1.  Quantitative proteomic determination of diethylstilbestrol action on prostate cancer.

Authors:  Pierre Bigot; Kevin Mouzat; Souhil Lebdai; Muriel Bahut; Nora Benhabiles; Géraldine Cancel Tassin; Abdel-Rahmène Azzouzi; Olivier Cussenot
Journal:  Asian J Androl       Date:  2013-02-25       Impact factor: 3.285

2.  Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy.

Authors:  Romain Mathieu; Shahrokh F Shariat; Christian Seitz; Pierre I Karakiewicz; Harun Fajkovic; Maxine Sun; Yair Lotan; Douglas S Scherr; Ashutosh Tewari; Francesco Montorsi; Alberto Briganti; Morgan Rouprêt; Ilaria Lucca; Vitaly Margulis; Michael Rink; Luis A Kluth; Malte Rieken; Alexander Bachman; Evanguelos Xylinas; Brian D Robinson; Karim Bensalah; Markus Margreiter
Journal:  World J Urol       Date:  2014-10-26       Impact factor: 4.226

3.  Immunohistochemical expression of minichromosome maintenance complex protein 2 predicts biochemical recurrence in prostate cancer: a tissue microarray and digital imaging analysis-based study of 428 cases.

Authors:  Antoun Toubaji; Siobhan Sutcliffe; Alcides Chaux; Kristen Lecksell; Jessica Hicks; Angelo M De Marzo; Elizabeth A Platz; George J Netto
Journal:  Hum Pathol       Date:  2012-05-02       Impact factor: 3.466

Review 4.  Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer.

Authors:  Roopali Roy; Jiang Yang; Marsha A Moses
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

5.  Characterization of prostate cancer incidentally detected in radical cystoprostatectomy specimens from Japanese men with bladder cancer.

Authors:  Toshifumi Kurahashi; Hideaki Miyake; Junya Furukawa; Masafumi Kumano; Atsushi Takenaka; Masato Fujisawa
Journal:  Int Urol Nephrol       Date:  2009-05-16       Impact factor: 2.370

6.  Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies.

Authors:  M S Tretiakova; W Wei; H D Boyer; L F Newcomb; S Hawley; H Auman; F Vakar-Lopez; J K McKenney; L Fazli; J Simko; D A Troyer; A Hurtado-Coll; I M Thompson; P R Carroll; W J Ellis; M E Gleave; P S Nelson; D W Lin; L D True; Z Feng; J D Brooks
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-05-03       Impact factor: 5.554

7.  Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival.

Authors:  Ferhat Ozden; Caner Saygin; Didem Uzunaslan; Bulent Onal; Haydar Durak; Hilal Aki
Journal:  J Cancer Res Clin Oncol       Date:  2013-05-25       Impact factor: 4.553

Review 8.  Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets.

Authors:  Elin Hadler-Olsen; Jan-Olof Winberg; Lars Uhlin-Hansen
Journal:  Tumour Biol       Date:  2013-05-17

9.  Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy.

Authors:  Janet M Pavese; Raymond C Bergan
Journal:  Cancer Lett       Date:  2014-07-10       Impact factor: 8.679

10.  Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement.

Authors:  C S Foster; A R Dodson; L Ambroisine; G Fisher; H Møller; J Clark; G Attard; J De-Bono; P Scardino; V E Reuter; C S Cooper; D M Berney; J Cuzick
Journal:  Br J Cancer       Date:  2009-08-25       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.